文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

抗坏血酸钠与抗坏血酸在脓毒症中的应用:心血管与神经获益新进展的叙述性综述

Sodium ascorbate versus ascorbic acid in sepsis: a narrative review of emerging cardiovascular and neurological benefits.
PubMed 文献 · Crit Care · 2026-01-03
一句话结论叙述性综述提示,pH中性的静脉抗坏血酸钠可能恢复去甲肾上腺素敏感性和额叶皮层微血管灌注与氧合,而传统抗坏血酸在临床试验中与 harm 相关。

脓毒症仍是全球ICU主要死因,去甲肾上腺素抵抗性休克治疗困难。抗坏血酸(维生素C)因支持内皮功能、降低氧化应激、激活免疫和促进内源性升压物质合成而成为潜在辅助治疗。传统静脉抗坏血酸在临床试验中与 harm 相关,而新兴临床前和早期临床数据显示,pH中性的静脉抗坏血酸钠可能恢复去甲肾上腺素敏感性和额叶皮层微血管灌注与氧合。本综述讨论抗坏血酸钠在脓毒症中的机制依据和治疗潜力,包括其穿越血脑屏障的能力。

要点

  • 脓毒症时血浆抗坏血酸水平显著耗竭,且与疾病严重程度相关。
  • 大脑皮层神经元主动富集抗坏血酸,浓度可高达血浆的250倍,对维持脑内氧化还原稳态和代谢至关重要。
  • 传统静脉抗坏血酸在临床试验中与 harm 相关;新兴临床前和早期临床数据提示静脉抗坏血酸钠可能恢复去甲肾上腺素敏感性。
  • 抗坏血酸钠可能重新建立额叶皮层微血管灌注和氧合,并具有穿越血脑屏障的能力。
  • 去甲肾上腺素是脓毒症低血压的主要升压药,但其效力常因肾上腺素能受体脱敏、一氧化氮过多、全身炎症和内皮损伤等多因素而受限。

适用人群与场景

  • 脓毒症患者,尤其是存在去甲肾上腺素抵抗性休克和脓毒症相关脑病风险者。

研究设计与关键结果

  • 本综述为叙述性综述,讨论抗坏血酸钠在脓毒症中的机制依据和治疗潜力,包括其穿越血脑屏障的能力。
  • 综述指出脓毒症时血浆抗坏血酸水平显著耗竭并与疾病严重程度相关,大脑皮层神经元主动富集抗坏血酸至血浆浓度的250倍。
  • 综述指出传统静脉抗坏血酸在临床试验中与 harm 相关,而新兴临床前和早期临床数据提示静脉抗坏血酸钠可能恢复去甲肾上腺素敏感性并重建额叶皮层微血管灌注和氧合。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 综述引用的证据包括临床前和早期临床数据,以及传统抗坏血酸临床试验中与 harm 相关的报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,抗坏血酸钠通过稳定心血管和脑血管功能,可能成为改善脓毒症管理的 promising 辅助治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis remains the leading cause of death in intensive care units globally, with catecholamine-resistant shock posing a persistent therapeutic challenge. Norepinephrine is the primary vasopressor used to treat hypotension in sepsis, but its efficacy is often limited by multifactorial loss of pressor responsiveness, including adrenergic receptor desensitisation, excess nitric oxide, systemic inflammation, and endothelial injury. Ascorbate (vitamin C) has emerged as a potential adjunct therapy because it supports endothelial function, reduces oxidative stress, activates the immune system and enhances endogenous vasopressor synthesis. Despite restoration of systemic hemodynamics with fluids and vasopressors, the frontal cortex remains particularly vulnerable to microcirculatory ischemia and hypoxia, contributing to sepsis-associated encephalopathy through hypoperfusion, hypoxia, hyperthermia, oxidative stress, neuroinflammation, and mitochondrial dysfunction, ultimately leading to neuronal injury and delirium. Plasma levels of ascorbate are profoundly depleted in sepsis and correlate with disease severity. Cerebral cortical neurons actively concentrate ascorbate at levels up to 250-fold higher than plasma, underscoring its importance in maintaining redox homeostasis and metabolism in the brain. While the conventional intravenous vitamin C formulation, ascorbic acid, has been associated with harm in clinical trials, emerging preclinical and early clinical data suggest that intravenous sodium ascorbate, a pH–neutral formulation of vitamin C, may restore noradrenaline sensitivity and re-establish frontal cortical microvascular perfusion and oxygenation. This review discusses the mechanistic rationale and therapeutic potential of sodium ascorbate in sepsis, including its ability to cross the blood-brain barrier. By stabilising cardiovascular and cerebrovascular function, sodium ascorbate may represent a promising adjunctive therapy to improve the management of sepsis.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bishop MS, Lane DJR, Ayton S, et al. Sodium ascorbate versus ascorbic acid in sepsis: a narrative review of emerging cardiovascular and neurological benefits. Crit Care. 2026. PMID: 41485064. doi:10.1186/s13054-025-05831-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。